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individual management of brain metastases using special 
radiotherapy protocols may improve both the patients’ 
survival and quality of life. We aimed at retrospectively 
studying the effects of low fraction dose whole-brain 
irradiation (WBRT) accompanied with simultaneous 
integrated boost (SIB). 
Materials and Methods: Between 2010 and 2013, 220 
patients with brain metastases were irradiated. Conventional 
WBRT (10 x 3 Gy) was delivered to 67 cases, who had a high 
number of metastasis. A SIB (15 x 0.7 Gy) dose in addition to 
WBRT (15 x 2.2 Gy) was applied in 153 cases with an average 
of 5 (1-14) metastases,. We assessed the overall survival (OS) 
in relation to the recursive partitioning analysis (RPA) value, 
the Karnofsky index and the metastasectomy (carried out or 
not) status of the patient. 
Results: The median OS of the WBRT-only and the WBRT+SIB 
groups was 3.7 and 6.4 months, respectively. In the 
WBRT+SIB group, the median OS was better in patients with 
RPA status 1 versus RPA status 2-3 (16.3 versus 5.3 months, 
p<0.0001), Karnofsky index ≥70% versus <70% (9.4 versus 4.4 
months, p<0.0001), and if metastasectomy was performed 
(8.0 versus 4.4 months, p<0.024). 
Conclusions: The differentiated treatment of patients with 
brain metastases according to the prognostic factors due to 
the higher cumulative dose of 3D-planned conformal 
radiotherapy delivered in a reasonable time may increase 
overall survival and possibly reduces the extent of late 
neurocognitive damage. 
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Purpose/Objective: There is an increasing evidence that 
multidisciplinary management of oligometastatic breast 
cancer with local therapy can improve disease control. The 
aim of our study is the assessment of safety and efficacy of 
SBRT in this selected subset of patients. 
Materials and Methods: Oligometastastic patients from 
breast cancer were treated with SBRT for 1-3 lung and liver 
lesions, in an observational study. Prescription dose ranged 
between 48 and 75 Gy in 3 or 4 consecutive fractions. 
Primary end-points were local control (LC). Secondary end-
point was toxicity, overall survival (OS) and progression-free 
survival (PFS). Local control was defined according to RECIST 
and PERCIST criteria. Toxicity was classified according to the 
Common Toxicity Criteria (CTC) version 3.0. 
Results: From February 2010 to November 2013, 29 patients 
were irradiated for a total number of 38 lesions. Twenty-one 
patients for a total of 27 liver lesions and 8 patients for a 
total of 11 lung lesions were treated. Median follow-up was 
20 (range 4 - 58) months. One and two- three years actuarial 
LC rate was 100% and 83% respectively. Complete response, 
partial response, stable disease and progression disease were 
detected in 24 (63%), 7 (19%), 4 (10%) and 3 (8%) lesions, 
respectively. Median overall survival (OS) was 39 months. 
Actuarial OS rate at 1, 2 and 3 years was 96%, 74 % and 60% 
respectively. Univariate analysis showed a correlation 
between OS and DFI > 5 years (p < 0.01). Median progression-
free survival (PFS) was 14 months, with a PFS rate at 1, 2 and 
3 years of 54%, 36% and 31% respectively. No patients 
experienced radiation-induced liver disease (RILD) or any 
grade >3 toxicity. 
Conclusions: SBRT is a safe and feasible alternative 
treatment of liver and lung oligometastases from breast 
cancer, in selected patients not amenable to surgery or other 
ablative treatments, with acceptable local control and 
survival rate. 
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Purpose/Objective: Long term follow up after re-irradiation 
of the spinal cord is lacking. The objective of the present 
study was therefore to evaluate the feasibility of health 
related quality of life measurements (HRQOL) measurements 
using the EQ5D-3L questionnaire following re-irradiation of 
metastatic spinal cord compression (MSCC). This is the first 
study to prospectively measure HRQOL in patients re-
irradiated for metastatic spinal cord compression 
Materials and Methods: During 2011 a total of 544 patients 
with acute symptoms of MSCC were enrolled in a prospective, 
consecutive cohort study. The Danish version of EQ5D was 
administered at baseline and 6, 12, 26 and 52 weeks after 
treatment. Nineteen patients received re-irradiation for 
progression at a previous irradiated site of the spine. A total 
of 15 patients answered one or more questionnaires; 7 
patients answered the questionnaire between the two 
treatments of radiotherapy and 8 patients answered the 
questionnaire after secondary treatment. No questionnaires 
were available in four patients.  
Results: Mean age was 63 years (range 43-81) with 3 men and 
5 women. Median survival after re-irradiation was 216 days 
(range 64-553). One patient was still alive at last follow-up. 
Diagnoses were two colon cancers, three lung cancers, one 
prostate cancer, one ovarian cancer and one bladder cancer. 
Median cumulative isoeffective prescribed dose in 2 Gy 
fractions was 62 Gy (range 47.7-84 Gy; α/β = 2). Distribution 
of answers is illustrated in Fig 1. In this strongly selected and 
small material answers for 'mobility' and 'pain' seems stable 
but 'usual activities' is declining until time of death. There 
were no reports of radiation induced myelopathy.  
